Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.

ABSTRACT:

Aims

Edoxaban, a novel factor Xa inhibitor, is a substrate of cytochrome P450 3 A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp). Three edoxaban drug-drug interaction studies examined the effects of P-gp inhibitors with varying degrees of CYP3A4 inhibition.

Methods

In each study, healthy subjects received a single oral dose of 60 mg edoxaban with or without an oral dual P-gp/CYP3A4 inhibitor as follows: ketoconazole 400 mg once daily for 7 days, edoxaban on day 4; erythromycin 500 mg four times daily for 8 days, edoxaban on day 7; or single dose of cyclosporine 500 mg with edoxaban. Serial plasma samples were obtained for pharmacokinetics and pharmacodynamics. Safety was assessed throughout the study.

Results

Coadministration of ketoconazole, erythromycin,

SUBMITTER: Parasrampuria DA 

PROVIDER: S-EPMC5099547 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature